Company intelligence / Profile preview

Nanomedicine & Nanodrugs ZPH

Ownership: Private
Development stage: Preclinical

Overview

Research shows their nanodrug caused significant changes in blood factors at 40 μg/ml concentration after two weeks of oral treatments, with increases in white blood cells and neutrophils and decreases in lymphocytes and cholesterol. In animal models, sick mice recovered completely from breast cancer with no evidence of tumor formation or metastasis in treated groups.

Therapeutic areas: Oncology
Modalities: NanodrugsQuantum dot nanoparticles (Q-Dot NPs)
Industry: Biotech

Beyond the preview

Go deeper on Nanomedicine & Nanodrugs ZPH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanomedicine & Nanodrugs ZPH.

Explore the full profile